NRG and Quirem Medical announce the first production for patient use at the NRG reactor

Deventer, August 7, 2019 – Today a first clinical QuiremScout patient procedure took place with radioactive holmium-166 microspheres that were activated at the NRG reactor in Petten, the Netherlands. QuiremScout is an innovative product for screening liver cancer patients before they are treated with QuiremSpheres.

“We are very pleased that after a period of extensive testing and validation, we can now use the NRG reactor for clinical productions.” says Jan Sigger, CEO of Quirem Medical. “NRG has proven to be a strong partner and we value their commitment during the development process leading up to this first clinical case. With the high availability and reliability of the NRG reactor, we are confident we can meet the strongly increasing demand for our products throughout Europe and beyond.”

“NRG is an internationally operating nuclear service provider, based in the Netherlands. NRG has a long-standing tradition of partnering with healthcare companies to produce medical isotopes. We are excited that we are now also able to support the production of holmium-166 microspheres, a true Dutch innovation.” says Huub Cuijpers, CEO of NRG.

QuiremScout is a unique product that allows for screening of patients that are candidates for Selective Internal Radiation Therapy (SIRT). QuiremScout is unique, as it is the only CE-marked product on the market for that purpose. It is more predictive than the current standard, Tech-99m-MAA.

QuiremSpheres, the next generation of radio-embolization microspheres, is the only commercially available SIRT product that contains holmium-166 microspheres. Unlike the widely adopted Yttrium-90 microspheres, holmium-166 microspheres can be visualized in low concentrations by means of Single Photon Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI). This allows clinicians to quantitatively assess the distribution of microspheres in the liver, enabling accurate evaluation of treatment directly after the radio-embolization procedure.

Share this post

Necessary cookies help make a website more usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.


Statistical cookies help us understand how visitors use the website by collecting and reporting data anonymously. These cookies therefore do not collect any personal data from visitors.

Cookies are small text files that can be used by websites to make user experiences more efficient. By law, we may store cookies on your device if they are strictly necessary for the use of the website. These are the functional cookies. We need your consent for all other types of cookies. These cookies are named as: preferences and statistics and you do not have to accept them. This website uses different types of cookies. Some cookies are placed by third party services that are displayed on our pages.

This website uses cookies to improve your experience. You can manage your options here.